EGFR and non-small cell lung carcinoma: Based on survival data from clinical trials, patients’ quality of life and current costs of medical resources, standard first‐generation EGFR‐TKI therapy remained the most cost‐effective treatment option for advanced EGFR‐mutant NSCLC patients comprehensively.